Your Health, We Care
The US Food and Drug Administration (FDA) has approved the combination standard treatment regimen of Quizartinib for the treatment of adult patients with FLT3-ITD positive AML.
The FDA has approved the LeukoStat CDx FLT3 mutation test as a companion diagnosis for Quizartinib, which helps to more accurately identify patient populations suitable for Quizartinib use.
